Risk of impaired coagulation in warfarin patients ascending to altitude (>2400 m)

High Altitude Medicine and Biology

Volumn 7, Issue 1, 2006, Pages 39-46

  Tissot van Patot, Martha C ^a   Hill, Ashley E ^b   Dingmann, Colleen ^a   Gaul, Lawrence ^c   Fralick, Kelly ^c   Christians, Uwe ^a   Honigman, Benjamin ^a   Salman, M D ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b Department of Environmental and Radiological Health Sciences   (United States)

^c Aurora Denver Cardiology Associates   (United States)

Author keywords

Anticoagulation; Atrial fibrillation; Hypoxia; International normalized ratio; Prothrombin time

Indexed keywords

COUMACARE; WARFARIN;

ALTITUDE DISEASE; ANTICOAGULANT THERAPY; BLOOD CLOTTING DISORDER; CARDIOMYOPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; HEART ATRIUM FIBRILLATION; HEART VALVE SURGERY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; MEDICAL RECORD; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; UNITED STATES;

ALTITUDE; ALTITUDE SICKNESS; ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD COAGULATION; CEREBROVASCULAR ACCIDENT; COLORADO; CONFIDENCE INTERVALS; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; ODDS RATIO; RETROSPECTIVE STUDIES; TRAVEL; WARFARIN;

EID: 33645638434     PISSN: 15270297     EISSN: None     Source Type: Journal    
DOI: 10.1089/ham.2006.7.39     Document Type: Review

References (18)

1. Andrus M.R. (2004). Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature. Pharmcotherapy 24(2):285-290.
2. Colorado Travel Year (2004). Longwoods International. Colorado Tourism Office. (http://www.colorado.com/docs/2004_FINAL_Longwoods_report.pdf). Last accessed January 30, 2006.
3. Comerford K.M., Wallace T.J., Karhausen J., Louis N.A., Montalto M.C., and Colgan S.P. (2002). Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 62(12): 3387-3394.
4. Earley S., Pastuszyn A., and Walker B.R. (2003). Cytochrome P-450 epoxygenase products contribute to attenuated vasoconstriction after chronic hypoxia. Am. J. Physiol. - Heart Circ. Physiol. 285(1): H127-136.
5. Feinberg W.M., Blackshear J.L., Laupacis A., Kronmal R., and Hart R.G. (1995). Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch. Intern. Med. 155(5): 469-473.
6. Grover R.F., and Bartsch P. (2001). Blood. In: High Altitude - An Exploration of Human Adaptation. T.F. Hornbein and R.B. Schoene, eds. Marcel Dekker, New York; pp. 493-523.
7. Habibzadeh F., and Yadollahie M. (1995). A simple method for the derivation of the international normalized ratio for the reporting of prothrombin time results. Am. J. Hematol. 50(4):283-287.
8. Hawk T.L., and Havrda D.E. (2002). Effect of stress on international normalized ratio during warfarin therapy. Ann. Pharmacother. 36(4):617-620.
9. Higashi M.K., Veenstra D.L., Kondo M.L., Wittkowsky A.K., Srinouanprachanh S.L., Farin F.M., and Rettie A.E. (2002). Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. J. Am. Med. Assoc. 287: 1690-1698.
10. Hopfl G., Ogunshola O., and Gassmann M. (2003). Hypoxia and high altitude. The molecular response. Adv. Exp. Med. Biol. 543:89-115.
11. Hylek E.M. (2003). Trends in anticoagulation management across community-based practices in the United States: the Anticoagulation Consortium to Improve Outcomes Nationally (ACTION) Study. J. Thromb. Thrombolysis 16(1-2):83-86.
12. Hylek E.M., Go A.S., Chang Y., Jensvold N.G., Henault L.E., Selby J.V., and Singer D.E. (2003). Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N. Engl. J. Med. 349(11): 1019-1026.
13. Jaillard. A.S., Hommel M., and Mazetti P. (1995). Prevalence of stroke at high altitude (3380 m) in Cuzco, a town of Peru. A population-based study. Stroke 26(4):562-568.
14. Jha S.K., Anand A.C., Sharma V., Kumar N., and Adya C.M. (2002). Stroke at high altitude: Indian experience. High Alt. Med. Biol. 3(1):21-27.
15. Kaminsky L.S., and Zhang Z.Y. (1997). Human P450 metabolism of warfarin. Pharmacol. Ther. 73(1): 67-74.
16. Streit M., Goggelnann C., Dehnert C., Burhenne J., Riedel K.-D., Menold E., Mikus G., Bartsch P., and Haefeli W.E. (2004). Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m). Eur. J. Clin. Pharmacol. 61(1):39-46.
17. Szutowski M.M., Łukasik M., Wawer Z.T., Chrobak K., Michalska. M., Borzüeckal K.B., and Brzezi J. (2002). In vivo effect of 5- and 8-methoxypsoralens and cimetidine on RS-warfarin metabolism in rat. J. Applied Toxicol. 22:327-332.
18. Wells P.S., Holbrook A.M., Crowther N.R., and Hirsh J. (1994). Interactions of warfarin with drugs and food. Ann. Intern. Med. 121(9):676-683.